Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations

World Journal of Hepatology

Volumn 5, Issue 10, 2013, Pages 528-540

  Zampino, Rosa ^a   Marrone, Aldo ^a   Restivo, Luciano ^a   Guerrera, Barbara ^a   Sellitto, Ausilia ^a   Rinaldi, Luca ^a   Romano, Ciro ^a   Adinolfi, Luigi E ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cytokines; Extra hepatic diseases; Hepatic disease; Hepatitis C virus; Inflammation; Oxidative stress

Indexed keywords

EID: 84887350238     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i10.528     Document Type: Review

References (144)

1. Kasprzak A, Zabel M, Biczysko W, Wysocki J, Adamek A, Spachacz R, Surdyk-Zasada J. Expression of cytokines (TNFalpha, IL-1alpha, and IL-2) in chronic hepatitis C: comparative hybridocytochemical and immunocytochemical study in children and adult patients. J Histochem Cytochem 2004; 52: 29-38 [PMID: 14688215 DOI: 10.1177/002215540405200104]
2. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-938 [PMID: 16107832 DOI: 10.1038/nature04077]
3. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19 [PMID: 14752815 DOI: 10.1002/hep.20032]
4. Núñez O, Fernández-Martínez A, Majano PL, Apolinario A, Gómez-Gonzalo M, Benedicto I, López-Cabrera M, Boscá L, Clemente G, García-Monzón C, Martín-Sanz P. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004; 53: 1665-1672 [PMID: 15479690 DOI: 10.1136/gut.2003.038364]
5. Gretton S, Hughes M, Harris M. Hepatitis C virus RNA replication is regulated by Ras-Erk signalling. J Gen Virol 2010; 91: 671-680 [PMID: 19889932 DOI: 10.1099/vir.0.016899-0]
6. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M, Fujisawa J, Okazaki K, Seki T. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46: 48-57 [PMID: 17596875 DOI: 10.1002/hep.21672]
7. Dalagiorgou G, Vassilaki N, Foka P, Boumlic A, Kakkanas A, Kochlios E, Khalili S, Aslanoglou E, Veletza S, Orfanoudakis G, Vassilopoulos D, Hadziyannis SJ, Koskinas J, Mavromara P. High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. J Gen Virol 2011; 92: 1343-1351 [PMID: 21307221 DOI: 10.1099/vir.0.023010-0]
8. Heydtmann M. Macrophages in hepatitis B and hepatitis C virus infections. J Virol 2009; 83: 2796-2802 [PMID: 18842723 DOI: 10.1128/JVI.00996-08]
9. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009; 58: 704-720 [PMID: 19359436 DOI: 10.1136/gut.2008.156307]
10. Lapinski TW. The levels of IL-1beta, IL-4 and IL-6 in the serum and the liver tissue of chronic HCV-infected patients. Arch Immunol Ther Exp (Warsz) 2001; 49: 311-316 [PMID: 11726034]
11. Burdette D, Haskett A, Presser L, McRae S, Iqbal J, Waris G. Hepatitis C virus activates interleukin-1ß via caspase-1-inflammasome complex. J Gen Virol 2012; 93: 235-246 [PMID: 21994322 DOI: 10.1099/vir.0.034033-0]
12. Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, Delker DA, Jo J, Bertoletti A, Hagedorn CH, Gale M. IL-1ß production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 2013; 9: e1003330 [PMID: 23633957 DOI: 10.1371/journal.ppat.1003330]
13. Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, Shimotohno K. HCV infection induces inflammatory cytokines and chemokines mediated by the cross-talk between hepatocytes and stellate cells. J Virol 2013; 87: 8169-8178 [DOI: 10.1128/JVI.00974-13]
14. Hosomura N, Kono H, Tsuchiya M, Ishii K, Ogiku M, Matsuda M, Fujii H. HCV-related proteins activate Kupffer cells isolated from human liver tissues. Dig Dis Sci 2011; 56: 1057-1064 [PMID: 20848204 DOI: 10.1007/s10620-010-1395-y]
15. Aroucha DC, do Carmo RF, Moura P, Silva JL, Vasconcelos LR, Cavalcanti MS, Muniz MT, Aroucha ML, Siqueira ER, Cahú GG, Pereira LM, Coêlho MR. High tumor necrosis factor-a/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C. Cytokine 2013; 62: 421-425 [PMID: 23602201 DOI: 10.1016/j.cyto.2013.03.024]
16. Neuman MG. Cytokines--central factors in alcoholic liver disease. Alcohol Res Health 2003; 27: 307-316 [PMID: 15540802]
17. Neuman MG, Schmilovitz-Weiss H, Hilzenrat N, Bourliere M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA, Cohen L. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int J Hepatol 2012; 2012: 231210 [PMID: 22530132 DOI: 10.1155/2012/231210]
18. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127: 1513-1524 [PMID: 15521019 DOI: 10.1053/j.gastro.2004.08.067]
19. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007; 82: 479-487 [PMID: 17595379 DOI: 10.1189/jlb.0207128]
20. Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D, Szabo G. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med 2012; 10: 151 [PMID: 22846613 DOI: 10.1186/1479-5876-10-151]
21. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141: 1220-1230, 1230.e1-e3 [PMID: 21726511]
22. Shimizu S, Yamada Y, Okuno M, Ohnishi H, Osawa Y, Seishima M, Moriwaki H. Liver injury induced by lipopolysaccharide is mediated by TNFR-1 but not by TNFR-2 or Fas in mice. Hepatol Res 2005; 31: 136-142 [PMID: 15715973 DOI: 10.1016/j.hepres.2004.11.012]
23. Brun P, Castagliuolo I, Pinzani M, Palù G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2005; 289: G571-G578 [PMID: 15860640 DOI: 10.1152/ajpgi.00537.2004]
24. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2634-2639 [PMID: 12385452 DOI: 10.1111/j.1572-0241.2002.06041.x]
25. Choi J, Forman HJ, Ou JH, Lai MM, Seronello S, Nandipati A. Redox modulation of the hepatitis C virus replication complex is calcium dependent. Free Radic Biol Med 2006; 41: 1488-1498 [PMID: 17023276 DOI: 10.1016/j.freeradbiomed.2006.08.008]
26. Sies H. Oxidative stress: introductory remarks. London: Academic Press, 1985
27. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306 [PMID: 11580156 DOI: 10.1016/S0168-8278(01)00142-8]
28. Diesen DL, Kuo PC. Nitric oxide and redox regulation in the liver: Part I. General considerations and redox biology in hepatitis. J Surg Res 2010; 162: 95-109 [PMID: 20444470 DOI: 10.1016/j.jss.2009.09.019]
29. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000; 21: 49-98 [PMID: 10978499 DOI: 10.1016/S0098-2997(00)00004-2]
30. Farinati F, Cardin R, Bortolami M, Burra P, Russo FP, Rugge M, Guido M, Sergio A, Naccarato R. Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J Viral Hepat 2007; 14: 821-829 [PMID: 18070284 DOI: 10.1111/j.1365-2893.2007.00878.x]
31. Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, Sutti S, Marrone A, Ruggiero G, Albano E, AdinolfiLE. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol 2008; 48: 399-406 [PMID: 18164507 DOI: 10.1016/j.jhep.2007.10.011]
32. AdinolfiLE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364 [PMID: 11391523 DOI: 10.1053/jhep.2001.24432]
33. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53: 791-799 [PMID: 21319195 DOI: 10.1002/hep.24123]
34. Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, Marrone A, Macera M, Sagnelli E, Perrone L, AdinolfiLE, Miraglia del Giudice E. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat 2013; 20: 517-523 [PMID: 23808989 DOI: 10.1111/jvh.12053]
35. Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008; 48: 80-87 [PMID: 18571785 DOI: 10.1002/hep.22311]
36. Palmer C, Corpuz T, Guirguis M, O'Toole S, Yan K, Bu Y, Jorgenson J, Talbot M, Loi K, Lloyd A, Zekry A. The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection. Gut 2010; 59: 397-404 [PMID: 19289381 DOI: 10.1136/gut.2008.165316]
37. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935 [PMID: 11344187 DOI: 10.1210/jc.86.5.1930]
38. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644 [PMID: 12939590 DOI: 10.1053/jhep.2003.50350]
39. Chang ML, Yeh CT, Lin DY, Ho YP, Hsu CM, Bissell DM. Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation. BMC Med Genomics 2009; 2: 51 [PMID: 19664232 DOI: 10.1186/1755-8794-2-51]
40. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, Powell EE. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004; 39: 1230-1238 [PMID: 15122751 DOI: 10.1002/hep.20179]
41. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, AdinolfiLE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642 [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014]
42. Lonardo A, AdinolfiLE, Petta S, Craxì A, Loria P. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther 2009; 7: 293-308 [PMID: 19344243 DOI: 10.1586/eri.09.3]
43. Sesti G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab 2006; 20: 665-679 [PMID: 17161338 DOI: 10.1016/j.beem.2006.09.007]
44. Knobler H, Schattner A. TNF-a, chronic hepatitis C and diabetes: a novel triad. QJM 2005; 98: 1-6 [PMID: 15625348 DOI: 10.1093/qjmed/hci001]
45. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005; 7: 1040-1052 [PMID: 15998259 DOI: 10.1089/ars.2005.7.1040]
46. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462 [PMID: 16968947 DOI: 10.1124/pr.58.3.2]
47. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Bátkai S. Endocannabinoids and the control of energy homeostasis. J Biol Chem 2008; 283: 33021-33025 [PMID: 18694938]
48. van der Poorten D, Shahidi M, Tay E, Sesha J, Tran K, McLeod D, Milliken JS, Ho V, Hebbard LW, Douglas MW, George J. Hepatitis C virus induces the cannabinoid receptor 1. PLoS One 2010; 5: pii: e12841[PMID: 20862263 DOI: 10.1371/journal.pone.0012841]
49. Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A, Pecker F, Mallat A, Lotersztajn S. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 2011; 54: 1217-1226 [PMID: 21735467 DOI: 10.1002/hep.24524]
50. Carrasquer A, Nebane NM, Williams WM, Song ZH. Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor. Pharmacogenet Genomics 2010; 20: 157-166 [PMID: 20124950 DOI: 10.1097/FPC.0b013e3283367c6b]
51. Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, Nobili B, Pasquale G, Maione S, AdinolfiLE, Perrone L, Sagnelli E, Miraglia Del Giudice E, Rossi F. Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. Clin Gastroenterol Hepatol 2013 May 22; Epub ahead of print [PMID: 23707465 DOI: 10.1016/j.cgh.2013.05.008]
52. Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I, Hassan S. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J 2011; 8: 53 [PMID: 21299910 DOI: 10.1186/1743-422X-8-53]
53. McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004; 53: 318-321 [PMID: 14960506 DOI: 10.1136/gut.2003.026393]
54. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol 2012 Jun 12; Epub ahead of print [PMID: 22688849 DOI: 10.1038/ajg.2012.137]
55. Costantini S, Capone F, Guerriero E, Maio P, Colonna G, Castello G. Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. Eur Cytokine Netw 2010; 21: 251-256 [PMID: 21081303 DOI: 10.1684/ecn.2010.0214]
56. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J, Sauerbruch T, Dienes HP, Odenthal M. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 2013; 58: 234-239 [PMID: 23085648 DOI: 10.1016/j.jhep.2012.10.015]
57. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, Mc-Caughan GW. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 2002; 160: 641-654 [PMID: 11839585 DOI: 10.1016/S0002-9440(10)64884-5]
58. Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, Merrell M, Soza A, Heller T, Ghany M, Park Y, Alter HJ, Hoofnagle JH, Murphy PM, Liang TJ. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124: 352-360 [PMID: 12557141 DOI: 10.1053/gast.2003.50061]
59. Mühlbauer M, BosserhoffAK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Schölmerich J, Hellerbrand C. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003; 125: 1085-1093 [PMID: 14517792 DOI: 10.1016/S0016-5085(03)01213-7]
60. Miyashita M, Ito T, Sakaki M, Kajiwara A, Nozawa H, Hiroishi K, Kobayashi M, Kumada H, Imawari M. Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. J Viral Hepat 2012; 19: 608-614 [PMID: 22863264 DOI: 10.1111/j.1365-2893.2011.01580]
61. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491 [PMID: 19224838 DOI: 10.1200/JCO.2008.20.7753]
62. Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY, Lee SD. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yixue Zazhi (Taipei) 1999; 62: 327-333 [PMID: 10389289]
63. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006; 80: 1197-1213 [PMID: 16946019 DOI: 10.1189/jlb.0506297]
64. Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa Y, Kinoshita H, Yamakado M, Kato N, Shiina S, Omata M. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 2009; 125: 2264-2269 [PMID: 19585572 DOI: 10.1002/ijc.24720]
65. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006; 387: 349-360 [PMID: 16606331 DOI: 10.1515/BC.2006.047]
66. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121: 2381-2386 [PMID: 17893868 DOI: 10.1002/ijc.23192]
67. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946-952 [PMID: 16107834 DOI: 10.1038/nature04079]
68. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371: 771-783 [PMID: 18275997 DOI: 10.1016/S0140-6736(08)60241-X]
69. Pal S, Polyak SJ, Bano N, Qiu WC, Carithers RL, Shuhart M, Gretch DR, Das A. Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol 2010; 25: 627-634 [PMID: 20074151 DOI: 10.1111/j.1440-1746.2009.06128.x]
70. Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, Fujii H, Rusyn I. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 2007; 14: 1182-1190 [PMID: 17195915 DOI: 10.1245/s10434-006-9049-1]
71. Adelman R, Saul RL, Ames BN. Oxidative damage to DNA: relation to species metabolic rate and life span. Proc Natl Acad Sci USA 1988; 85: 2706-2708 [PMID: 3128794 DOI: 10.1073/pnas.85.8.2706]
72. Konishi M, Iwasa M, Araki J, Kobayashi Y, Katsuki A, Sumida Y, Nakagawa N, Kojima Y, Watanabe S, Adachi Y, Kaito M. Increased lipid peroxidation in patients with nonalcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol 2006; 21: 1821-1825 [PMID: 17074020 DOI: 10.1111/j.1440-1746.2006.04420.x]
73. Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RL, Larson AM, Yeh MM, Camp DG, Smith RD, Katze MG. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 2007; 46: 649-657 [PMID: 17654742 DOI: 10.1002/hep.21751]
74. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3: 276-285 [PMID: 12671666 DOI: 10.1038/nrc1046]
75. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003; 34: 955-968 [PMID: 12684081 DOI: 10.1016/S0891-5849(02)01363-1]
76. Lirk P, Hoffmann G, Rieder J. Inducible nitric oxide synthase--time for reappraisal. Curr Drug Targets Inflamm Allergy 2002; 1: 89-108 [PMID: 14561209 DOI: 10.2174/1568010023344913]
77. Szabó C, Ohshima H. DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1997; 1: 373-385 [PMID: 9441908 DOI: 10.1006/niox.1997.0143]
78. Capone F, Costantini S, Guerriero E, Calemma R, Napolitano M, Scala S, Izzo F, Castello G. Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 2010; 21: 99-104 [PMID: 20478763 DOI: 10.1684/ecn.2010.0192]
79. Sansonno D, Lauletta G, Nisi L, Gatti P, Pesola F, Pansini N, Dammacco F. Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clin Exp Immunol 2003; 133: 275-282 [PMID: 12869035 DOI: 10.1046/j.1365-2249.2003.02204.x]
80. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495 [PMID: 1383822 DOI: 10.1056/NEJM199211193272104]
81. Agnello V. Hepatitis C virus infection and type II cryoglobulinemia: an immunological perspective. Hepatology 1997; 26: 1375-1379 [PMID: 9397973 DOI: 10.1002/hep.510260642]
82. AdinolfiLE, Utili R, Attanasio V, Zampino R, Ragone E, Tripodi MF, Ruggiero G. Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol 1996; 28: 1-9 [PMID: 8743066]
83. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002; 46: 585-597 [PMID: 11920393 DOI: 10.1002/art.10107]
84. Donada C, Crucitti A, Donadon V, Tommasi L, Zanette G, Crovatto M, Santini GF, Chemello L, Alberti A. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. J Viral Hepat 1998; 5: 179-185 [PMID: 9658371 DOI: 10.1046/j.1365-2893.1998.00097.x]
85. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011; 117: 1792-1798 [PMID: 20959600 DOI: 10.1182/blood-2010-06-275818]
86. Gabrielli A, Zhang ZX, Cherubini G, Candela M, Savoldi S, Manzin A, Clementi M, Amoroso A, Sallberg M. Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol 1996; 105: 59-64 [PMID: 8697636 DOI: 10.1046/j.1365-2249.1996.d01-720.x]
87. Ghebrehiwet B, Peerschke EI. Structure and function of gC1q-R: a multiligand binding cellular protein. Immunobiology 1998; 199: 225-238 [PMID: 9777408 DOI: 10.1016/S0171-2985(98)80029-6]
88. Sansonno D, Tucci FA, Ghebrehiwet B, Lauletta G, Peerschke EI, Conteduca V, Russi S, Gatti P, Sansonno L, Dammacco F. Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J Immunol 2009; 183: 6013-6020 [PMID: 19828637 DOI: 10.4049/jimmunol.0902038]
89. Hu YW, Rocheleau L, Larke B, Chui L, Lee B, Ma M, Liu S, Omlin T, Pelchat M, Brown EG. Immunoglobulin mimicry by Hepatitis C Virus envelope protein E2. Virology 2005; 332: 538-549 [PMID: 15680419 DOI: 10.1016/j.virol.2004.11.041]
90. Chandra PK, Hazari S, Poat B, Gunduz F, Prabhu R, Liu G, Burioni R, Clementi M, Garry RF, Dash S. Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virol J 2010; 7: 118 [PMID: 20529250 DOI: 10.1186/1743-422X-7-118]
91. Ishizaka N, Ishizaka Y, Takahashi E, Tooda Ei, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359: 133-135 [PMID: 11809259 DOI: 10.1016/S0140-6736(02)07339-7]
92. Ishizaka Y, Ishizaka N, Takahashi E, Unuma T, Tooda E, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 2003; 67: 26-30 [PMID: 12520147 DOI: 10.1253/circj.67.26]
93. Völzke H, Schwahn C, WolffB, Mentel R, Robinson DM, Kleine V, Felix SB, John U. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 2004; 174: 99-103 [PMID: 15135257 DOI: 10.1016/j.atherosclerosis.2004.01.010]
94. AdinolfiLE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCVrelated steatosis. Atherosclerosis 2012; 221: 496-502 [PMID: 22385985 DOI: 10.1016/j.atherosclerosis.2012.01.051]
95. Vassalle C, Masini S, Bianchi F, Zucchelli GC. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004; 90: 565-566 [PMID: 15084562 DOI: 10.1136/hrt.2003.018937]
96. Butt AA, Xiaoqiang W, BudoffM, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225-232 [PMID: 19508169 DOI: 10.1086/599371]
97. Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A populationbased cohort study. PLoS One 2012; 7: e31527 [PMID: 22363662 DOI: 10.1371/journal.pone.0031527]
98. Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin Biochem 2001; 34: 167-171 [PMID: 11408013 DOI: 10.1016/S0009-9120(01)00210-7]
99. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890 [PMID: 11742859 DOI: 10.1161/hq1201.100220]
100. Abbas Z, Moatter T. Interleukin (IL) 1beta and IL-10 gene polymorphism in chronic hepatitis C patients with normal or elevated alanine aminotransferase levels. J Pak Med Assoc 2003; 53: 59-62 [PMID: 12705485]
101. Tsui JI, Whooley MA, Monto A, Seal K, Tien PC, Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail 2009; 15: 451-456 [PMID: 19477406 DOI: 10.1016/j.cardfail.2008.12.003]
102. Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, Coady E, Esmat G, El-Hoseiny M, Abdul-Hamid M, Hughes A, Chaturvedi N. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010; 59: 1135-1140 [PMID: 20584782 DOI: 10.1136/gut.2009.202317]
103. Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, Marini SS, Barbeiro HV, Soriano FG, Carrilho FJ, Pereira LM, Alvares-da-Silva MR. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol 2013; 164: 221-226 [PMID: 21784542 DOI: 10.1016/j.ijcard.2011.07.016]
104. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, CioffiM, Ruggiero G, AdinolfiLE. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factoralpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006; 24: 1349-1357 [PMID: 17059516 DOI: 10.1111/j.1365-2036.2006.03114.x]
105. Boddi M, Abbate R, Chellini B, Giusti B, Solazzo V, Soft F, Pratesi G, Pratesi C, Gensini G, Zignego AL. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis 2007; 39 Suppl 1: S55-S60 [PMID: 17936225 DOI: 10.1016/S1590-8658(07)80012-0]
106. Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, Pratesi G, Rossi L, Pratesi C, Gensini GF, Paperetti L, Zignego AL. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 2010; 47: 72-75 [PMID: 19896417 DOI: 10.1016/j.jcv.2009.10.005]
107. Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, Schminke U, Kessler C, John U. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005; 11: 1848-1853 [PMID: 15793879]
108. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A, Fargion S. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008; 121: 72-78 [PMID: 18187076 DOI: 10.1016/j.amjmed.2007.08.041]
109. Gastaldelli A, Basta G. Ectopic fat and cardiovascular disease: what is the link? Nutr Metab Cardiovasc Dis 2010; 20: 481-490 [PMID: 20659791 DOI: 10.1016/j.numecd.2010.05.005]
110. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, AdinolfiLE, Ruggiero G, Carulli N, Loria P. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006; 44: 190-196 [PMID: 16168516 DOI: 10.1016/j.jhep.2005.06.018]
111. Vivona N, Bivona G, Noto D, Sasso BL, Cefalù AB, Chiarello G, Falletta A, Ciaccio M, Averna MR. C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. Clin Biochem 2009; 42: 1713-1718 [PMID: 19732763 DOI: 10.1016/j.clinbiochem]
112. Antonelli A, Ferri C, Ferrari SM, Galetta F, Franzoni F, Santoro G, De Marco S, Ghiri E, Fallahi P. High circulating N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha in mixed cryoglobulinemia. World J Gastroenterol 2009; 15: 5074-5079 [PMID: 19860001 DOI: 10.3748/wjg.15.5074]
113. Giannakoulas G, Hatzitolios A, Karvounis H, Koliakos G, Charitandi A, Dimitroulas T, Savopoulos C, Tsirogianni E, Louridas G. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology 2005; 56: 723-730 [PMID: 16327949 DOI: 10.1177/000331970505600610]
114. Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis 2004; 19: 351-356 [PMID: 15554427]
115. Goh J, Coughlan B, Quinn J, O'Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999; 11: 833-838 [PMID: 10514113 DOI: 10.1097/00042737-199908000-00004]
116. Seifert F, Struffert T, Hildebrandt M, Blümcke I, Brück W, Staykov D, Huttner HB, Hilz MJ, Schwab S, Bardutzky J. In vivo detection of hepatitis C virus (HCV) RNA in the brain in a case of encephalitis: evidence for HCV neuroinvasion. Eur J Neurol 2008; 15: 214-218 [PMID: 18215154 DOI: 10.1111/j.1468-1331.2007.02044.x]
117. Bokemeyer M, Ding XQ, Goldbecker A, Raab P, Heeren M, Arvanitis D, Tillmann HL, Lanfermann H, Weissenborn K. Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy. Gut 2011; 60: 370-377 [PMID: 20926642 DOI: 10.1136/gut.2010.217976]
118. Fletcher NF, McKeating JA. Hepatitis C virus and the brain. J Viral Hepat 2012; 19: 301-306 [PMID: 22497808 DOI: 10.1111/j.1365-2893.2012.01591]
119. Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. HCV-related nervous system disorders. Clin Dev Immunol 2012; 2012: 236148 [PMID: 22899946 DOI: 10.1155/2012/236148]
120. Palin K, Bluthé RM, McCusker RH, Moos F, Dantzer R, Kelley KW. TNFalpha-induced sickness behavior in mice with functional 55 kD TNF receptors is blocked by central IGF-I. J Neuroimmunol 2007; 187: 55-60 [PMID: 17512609 DOI: 10.1016/j.jneuroim.2007.04.011]
121. McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, Heathcote EJ. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801-808 [PMID: 15793853 DOI: 10.1002/hep.20635]
122. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9: 847-854 [PMID: 14632243 DOI: 10.1017/S1355617703960048]
123. Senzolo M, SchiffS, D'Aloiso CM, Crivellin C, Cholongitas E, Burra P, Montagnese S. Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol 2011; 17: 3369-3374 [PMID: 21876628 DOI: 10.3748/wjg.v17.i29.3369]
124. Origgi L, Vanoli M, Carbone A, Grasso M, Scorza R. Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci 1998; 315: 208-210 [PMID: 9519936 DOI: 10.1097/00000441-199803000-00012]
125. Ramos-Casals M, Robles A, Brito-Zerón P, Nardi N, Nicolás JM, Forns X, Plaza J, Yagüe J, Sánchez-Tapias JM, Font J. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006;36: 189-196 [PMID: 16996578 DOI: 10.1016/j.semarthrit.2006.08.005]
126. Petty GW, Duffy J, Houston J. Cerebral ischemia in patients with hepatitis C virus infection and mixed cryoglobulinemia. Mayo Clin Proc 1996; 71: 671-678 [PMID: 8656709 DOI: 10.1016/S0025-6196(11)63005-X]
127. Cacoub P, Sbaï A, Hausfater P, Papo T, Gatel A, Piette JC. [Central nervous system involvement in hepatitis C virus infection]. Gastroenterol Clin Biol 1998; 22: 631-633 [PMID: 9762334]
128. Carta MG, Angst J, Moro MF, Mura G, Hardoy MC, Balestrieri C, Chessa L, Serra G, Lai ME, Farci P. Association of chronic hepatitis C with recurrent brief depression. J Affect Disord 2012; 141: 361-366 [PMID: 22609196 DOI: 10.1016/j.jad.2012.03.020]
129. Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe IA, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, McKeating JA. Hepatitis C virus infects the endothelial cells of the bloodbrain barrier. Gastroenterology 2012; 142: 634-643.e6 [PMID: 22138189 DOI: 10.1053/j.gastro.2011.11.028]
130. Chen KJ, Tseng CK, Chang FR, Yang JI, Yeh CC, Chen WC, Wu SF, Chang HW, Lee JC. Aqueous extract of the edible Gracilaria tenuistipitata inhibits hepatitis C viral replication via cyclooxygenase-2 suppression and reduces virusinduced inflammation. PLoS One 2013; 8: e57704 [PMID: 23469054 DOI: 10.1371/journal.pone.0057704]
131. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, Atzeni F, Saccardo F, Quartuccio L, Bruno S, Bruno R, Campanini M, Candela M, Castelnovo L, Gabrielli A, Gaeta GB, Marson P, Mascia MT, Mazzaro C, Mazzotta F, Meroni P, Montecucco C, Ossi E, Piccinino F, Prati D, Puoti M, Riboldi P, Riva A, Roccatello D, Sagnelli E, Scaini P, Scarpato S, Sinico R, Taliani G, Tavoni A, Bonacci E, Renoldi P, Filippini D, Sarzi-Puttini P, Ferri C, Monti G, Galli M. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011; 10: 444-454 [PMID: 21303705 DOI: 10.1016/j.autrev.2011.01.008]
132. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggiò MA, Chironna M, Sansonno D. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116: 343-353 [PMID: 20308602 DOI: 10.1182/blood-2009-10-245878]
133. Castello G, Costantini S, Scala S. Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med 2010; 8: 109 [PMID: 21047421 DOI: 10.1186/1479-5876-8-109]
134. Dinarello CA. A clinical perspective of IL-1ß as the gatekeeper of inflammation. Eur J Immunol 2011; 41: 1203-1217 [PMID: 21523780 DOI: 10.1002/eji.201141550]
135. Lonardo A, Ballestri R, Restivo L, AdinolfiLE, Loria P. Hepatitis C and cardiovascular risk: facts and controversies. 3rd ed. In: F Negro. Hot Topic in Viral Hepatitis. Modena: FBCommunication, 2012: 27-35 Available from: URL: http//www.hottopicsin.com.
136. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1946-1952 [PMID: 15447754 DOI: 10.1111/j.1572-0241.2004.40220.x]
137. Whitehouse MW. Anti-TNF-alpha therapy for chronic inflammation: reconsidering pentoxifylline as an alternative to therapeutic protein drugs. Inflammopharmacology 2004; 12: 223-227 [PMID: 15527546 DOI: 10.1163/1568560042342293]
138. Austin AS, Mahida YR, Clarke D, Ryder SD, Freeman JG. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol Ther 2004; 19: 79-88 [PMID: 14687169 DOI: 10.1046/j.1365-2036.2003.01809.x]
139. Hernández E, Correa A, Bucio L, Souza V, Kershenobich D, Gutiérrez-Ruiz MC. Pentoxifylline diminished acetaldehydeinduced collagen production in hepatic stellate cells by decreasing interleukin-6 expression. Pharmacol Res 2002; 46: 435-443 [PMID: 12419648 DOI: 10.1016/S1043661802002025]
140. Coimbra R, Porcides RD, Melbostad H, Loomis W, Tobar M, Hoyt DB, Wolf P. Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia. Surg Infect (Larchmt) 2005; 6: 73-85 [PMID: 15865553 DOI: 10.1089/sur.2005.6.73]
141. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, Schuppan D. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002; 50: 241-247 [PMID: 11788567 DOI: 10.1136/gut.50.2.241]
142. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997; 29: 181-196 [PMID: 9251897 DOI: 10.1016/S0306-3623(96)00314-X]
143. Gutierrez-Reyes G, Lopez-Ortal P, Sixtos S, Cruz S, Ramirez-Iglesias MT, Gutierrez-Ruiz MC, Sanchez-Avila F, Roldan E, Vargas-Vorackova F, Kershenobich D. Effect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis C. Scand J Immunol 2006; 63: 461-467 [PMID: 16764700 DOI: 10.1111/j.1365-3083.2006.001761.x]
144. Mallat A, Teixeira-Clerc F, Lotersztajn S. Cannabinoid signaling and liver therapeutics. J Hepatol 2013; 59: 891-896 [PMID: 23567085 DOI: 10.1016/j.jhep.2013.03.032]